Retrophin to Present at Upcoming Investor Conferences
November 11, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November...
Retrophin Reports Third Quarter 2020 Financial Results
November 05, 2020 16:01 ET
|
Retrophin, Inc.
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21 Pivotal PROTECT Study achieved enrollment of 280th patient with IgAN to enable...
Retrophin Announces Agreement to Acquire Orphan Technologies
October 22, 2020 16:01 ET
|
Retrophin, Inc.
Agreement adds OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria Compelling strategic fit that will expand pipeline of potential...
Retrophin Reports Second Quarter 2020 Financial Results
July 30, 2020 16:01 ET
|
Retrophin, Inc.
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased...
Retrophin to Report Second Quarter 2020 Financial Results
July 16, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the...
Retrophin Announces Proposed Public Offering of Common Stock
June 08, 2020 16:01 ET
|
Retrophin, Inc.
SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, subject...
Retrophin Reports First Quarter 2020 Financial Results
May 11, 2020 16:01 ET
|
Retrophin, Inc.
Enrollment continues in the pivotal DUPLEX and PROTECT studies of sparsentan DUPLEX Study of sparsentan in FSGS enrolled first 190 patients required for interim proteinuria analysis Net product...
Retrophin to Report First Quarter 2020 Financial Results
April 27, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2020 financial results on Monday, May 11, 2020 after the close of the U.S....
Retrophin Appoints Suzanne L. Bruhn, Ph.D. to Board of Directors
April 09, 2020 16:30 ET
|
Retrophin, Inc.
SAN DIEGO, April 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Suzanne L. Bruhn, Ph.D. to the Company’s Board of Directors, effective immediately....
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 DUPLEX Study of Sparsentan in Focal Segmental Glomerulosclerosis
March 09, 2020 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, March 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating the safety...